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Abstract
Background: Pancreatectomy has a high morbidity but remains the only chance of cure for
pancreatic cancer. Its efficacy for non-pancreatic malignancies is less clear. We reviewed our
experience with pancreatectomy for non-pancreatic malignancies to determine outcomes and
identify predictors of survival.
Patients and methods: The records of patients who underwent pancreatectomy for non-
pancreatic malignancies between 1990 and 2005 were reviewed. Survival curves were constructed
using the Kaplan-Meier method and compared using log-rank analysis. Cox proportional hazards
was used to identify predictors of survival.
Results:  29 patients (18 M/11 F) with a mean age of 59.9 years (range 29–86) underwent
pancreatectomy for non-pancreatic malignancies. 19 (66%) primary malignancies were GI in origin.
Most operations were undertaken with curative intent (76%), whereas the remainder was for
symptom palliation. Pancreatectomy was completed for metastatic disease in 7 patients (24%) or
en bloc to achieve negative margins in 22 patients (76%). Complete (i.e., R0) resection was achieved
in 17 (59%). Perioperative mortality was 3%. Median follow-up was 15 months (range 7–172).
Median overall survival was 12 months with 1-year survival of 48%. Significant predictors of
improved survival by univariate analysis were R0 resection, non-GI primary, and pancreatic
metastasectomy (vs. en bloc resection). Only R0 resection was predictive of long-term survival by
multivariate analysis (median 21 months vs. 6).
Conclusion: Pancreatic resection for non-pancreatic malignancies can be completed with minimal
mortality. However, incomplete resection results in poor overall survival. Pancreatectomy for non-
pancreatic malignancies should only be undertaken if complete resection is possible.
Background
Pancreatic metastases represent an unusual clinical pres-
entation. Sperti et al, in a literature review of 2044
reported pancreatic resections, found that only 46 (1.4%)
were performed for secondary tumors [1]. Interestingly,
the prevalence of metastases to the pancreas at autopsy is
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reported to be as high as 11%; the majority of these occur
in patients with disseminated intraabdominal metastases
[2]. Tumors that most commonly metastasize to the pan-
creas by blood-borne dissemination include renal cell car-
cinoma, melanoma, and breast and lung carcinomas.
Colon carcinoma may involve the pancreas by direct inva-
sion [3]. Up to 50% of patients with metastatic lesions are
asymptomatic, the metastasis being detected upon rou-
tine surveillance for the primary tumor [3]. The differen-
tial diagnosis of metastases to the pancreas as compared
to primary pancreatic tumors can be difficult. The pres-
ence of multiple hypervascular lesions on imaging studies
suggests pancreatic metastasis (whereas primary pancre-
atic tumors are commonly hypovascular), but primary
neuroendocrine tumor of the pancreas must be ruled out
[3].
It is well documented that resection of hepatic metastases
from colorectal carcinoma, sarcoma, or renal cell carci-
noma achieves good survival. Similarly, resections of met-
astatic disease to the lungs and brain are now routinely
undertaken. However, guidelines for pancreatic resection
for metastatic disease remain unclear, probably due to the
rarity of these tumors. While some recommend resection
of pancreatic metastases only when there is no evidence of
extrapancreatic disease [4], others maintain that the pres-
ence of extrapancreatic disease is not a contraindication,
provided that complete resection can be achieved [1,5].
Previous reports of small numbers of patients undergoing
pancreatic resection for metastatic lesions have demon-
strated median overall survivals of 19–42 months.
Selected patients, particularly those with renal cell carci-
noma, can achieve long-term survival [1,3,5-11]. These
results, along with the decreased morbidity and mortality
of pancreatic resection currently obtained in experienced
centers, support the aggressive management of pancreatic
metastases in selected patients.
We report herein our single-institution experience with 29
pancreatic resections for non-primary lesions of the pan-
creas, including metastases to the pancreas from previ-
ously resected primaries, as well as intraabdominal
tumors with direct extension to the pancreas. We sought
to determine the morbidity and mortality of pancreatic
resection in patients with nonpancreatic malignancies
and to identify factors predictive of overall survival.
Patients and methods
Patients
The records of patients who underwent pancreatectomy
for non-pancreatic malignancies at the Ohio State Univer-
sity Medical Center between 1990 and 2005 (n = 29) were
retrospectively reviewed. Both computerized records and
paper charts were examined. Approval for this review was
obtained from the Institutional Review Board of the Ohio
State University.
Eligibility criteria and patient follow-up
Preoperative evaluation included history and physical
examination; laboratory studies including complete
blood count, serum chemistry, and coagulation profile;
CT of the abdomen; and other imaging studies as appro-
priate. For patients presenting with pancreatic metastases,
records from resection of the primary tumor were also
reviewed. Eligibility criteria included the ability to obtain
complete resection of the metastatic lesion and/or pri-
mary lesion with direct extension to the pancreas, as deter-
mined by preoperative imaging assessment; and the
absence of medical comorbidities precluding operation. A
minority of patients underwent operation with palliative
intent. Postoperatively, patients underwent clinical and
radiologic evaluation at the discretion of the attending
physician.
Statistical methods
Overall survival was determined from the date of surgery
until death from any cause as determined by hospital
records or the Social Security Death Index [12] as of May
29, 2007. Survival curves were constructed using the Kap-
lan-Meier method and comparisons between curves were
made using log-rank analysis. All statistical analyses were




Between 1990 and 2005, a total of 29 patients (18 male,
11 female; mean age 59.9 years, range 29–86) underwent
pancreatectomy for non-pancreatic malignancies at the
Ohio State University Medical Center (Table 1). The
majority of the operations (76%) were undertaken with
curative intent, and the remainder was for symptom palli-
ation. Involvement of the pancreas by direct extension of
malignancy occurred in 22 (76%) patients, whereas met-
achronous metastases to the pancreas from distant sites
occurred in 7 (24%) patients (kidney, 4; brain, 1; esopha-
gus, 1; chondrosarcoma, 1). Nineteen primaries (66%)
were of GI origin. The most common sites of primary
malignancy were colorectal, gastric, and renal cell carci-
noma. The majority of patients (21) underwent distal
pancreatectomy; 7 underwent pancreaticoduodenectomy
and one underwent total pancreatectomy. The median
time from primary resection to pancreatic metastasis/
extension was 52 months (range, 13–240). Complete
(R0) resection was achieved in 17 patients (59%).
Morbidity
Operative mortality was 3.4% (one patient). Fifteen
patients (51.7%) had a total of 20 complications (TableWorld Journal of Surgical Oncology 2007, 5:145 http://www.wjso.com/content/5/1/145
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2). Overall morbidity in this study was similar to that
reported by others [3,13]. The most common GI-related
complication was pancreatic fistula (4 patients, 13.8%),
followed by intraabdominal abscess and pancreatitis.
Pancreatic fistula was defined as drainage of amylase-rich
fluid any time after the third postoperative day. The most
common non-GI complication was pneumonia (4
patients, 13.8%). Two patients developed deep venous
thrombosis. Six patients (20.7%) had complications
requiring reoperation. Of these, three patients were
explored for small bowel obstructions failing non-opera-
tive management. One underwent operation two weeks
after pancreatectomy for lysis of adhesions and again at
three months for recurrent obstruction, and the other two
underwent laparotomy for small bowel obstruction at one
and six months postoperative, respectively. One patient
underwent revision of gastrojejunostomy at six weeks
postoperative, and one underwent exploration for control
of gastrointestinal hemorrhage one month after the index
operation. Finally, one patient was explored at nine
months for small bowel obstruction and was found to
have recurrent disease. The incidence of complications
among those undergoing R0 resection was not different
than that of patients undergoing R1 or R2 resection (p = 1,
Fisher's exact test). Similarly, the incidence of complica-
tions among patients undergoing distal pancreatectomy
was not different than that of patients undergoing resec-
tion other than distal pancreatectomy (p = 0.25, Fisher's
exact test).
Survival and prognostic factors
The median length of hospital stay was 12 days (range, 7–
43). At a mean follow-up of 14.2 months (range, 1–118),
median overall survival was 12 (95% CI 6.4, 17.6)
months. 12- and 24-month survival was 48% and 20%,
respectively. At the time of analysis, seven patients (24%)
were still alive. First, the ability to obtain R0 resection was
examined. R0 resection was achieved in 77% of opera-
tions undertaken for curative intent, as compared to 0% of
operations performed with palliative intent (Table 3).
Patients for whom R0 resection was achieved had median
overall survival of 21 (95% CI 3.5, 38.5) months, as com-
pared to six (95% CI 3.5, 8.5) months for those who had
R1 or R2 resection (p = 0.035; Figure 1). Predictors of
improved survival by univariate analysis were R0 resec-
tion, non-GI primary, and metastasectomy as opposed to
en bloc resection (Table 4). By multivariate analysis, only
R0 resection was predictive of long-term survival (Table
4). We examined the same set of variables used to evaluate
survival (i.e., age, gender, primary site, synchronous ver-
sus metachronous disease, disease free interval, curative
versus palliative intent, extent of pancreatectomy, metas-
tasectomy versus en bloc resection and R0 versus R1/2
Table 2: Operative complications.
Event Number (percent)
Mortality 1 (3.4)
Complications (number of 
patients)
15 (51.7)
Complications (total number) 20
Pancreatic fistula 4 (13.8)
Intraabdominal abscess 2 (6.9)
Pancreatitis 2 (6.9)
Small bowel perforation with 
enterocutaneous fistula
1 (3.4)
Anastamotic leak 1 (3.4)
Prolonged ileus 2 (6.9)
Pneumonia 4 (13.8)
Deep vein thrombosis 2 (6.9)
Cerebrovascular accident 1 (3.4)
Wound infection 1 (3.4)
Required reoperation 6 (20.7)












Indication for pancreatic resection
En bloc for direct extension of primary malignancy 22 (76)
Metachronous metastasis to pancreas 7(24)
Site of primary tumor
Colorectal 9 (31.0)
Gastric 8 (27.6)
Renal cell carcinoma 5 (17.2)
Mesenteric fibromatosis 2 (6.9)







Moderately differentiated adenocarcinoma 10 (34.5)
Poorly differentiated adenocarcinoma 5 (17.2)
Mucinous adenocarcinoma 1 (3.4)
Adenocarcinoma not otherwise specified 3 (10.3)
Signet ring 1 (3.4)
Clear cell 5 (17.2)
Mesenteric fibrosis 2 (6.9)
Hemangiopericytoma 1 (3.4)
Chondrosarcoma 1 (3.4)





R0 (complete resection) 17 (59)
R1 (incomplete resection with microscopic disease) 4 (14)
R2 (grossly incomplete resection) 8 (27)World Journal of Surgical Oncology 2007, 5:145 http://www.wjso.com/content/5/1/145
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resection) for potential predictors of R0 resection. No fac-
tors capable of predicting R0 resection were identified.
Next, the primary site was examined. Among patients who
underwent en bloc resection for local extension to the
pancreas (n = 22), R0 resection was achieved in 12
patients (55%), as compared to 5 of 7 patients (71%) who
underwent resection for metastases to the pancreas (Table
3) (p = 0.37, Fisher's exact test). Finally, patients with non-
GI primaries had improved median overall survival as
compared to those with GI primaries: 31 (95% CI 0.0,
61.8) months versus 8 (95% CI 4.6, 11.4) months (p =
0.025; Figure 2).
Discussion
Herein we report one of the largest single-institution expe-
riences with pancreatectomy for locally advanced or recur-
rent non-pancreatic tumors. The majority of these
operations were undertaken with curative intent, com-
plete (i.e. R0) resection being achieved in 77%. Palliative
pancreatectomy, however, did not result in complete
tumor clearance in any patient, and was associated with
poorer survival. While perioperative mortality was rare
(one patient), morbidity was substantial, reflecting the
magnitude of the operations performed.
Survival for gastrointestinal primary as compared to non-gas- trointestinal primary Figure 2
Survival for gastrointestinal primary as compared to 
non-gastrointestinal primary. The solid line represents 
patients with non-GI primaries, and the dashed line repre-
sents patients with GI primaries.
Table 4: Univariate and multivariate analyses for predictors of 
overall survival. Variables with the greatest potential impact on 
overall survival by univariate analysis (p ≤ 0.2) were entered into 
the multivariate model using Cox Proportional Hazards analysis. 
Data represent p values.
Univariate Multivariate
Age (>60 vs. ≤60) 0.47 --
Age (continuous) 0.52 --
Gender 0.92 --
Primary site 0.20 0.96
Synchronous vs. metachronous 0.14 0.69
Disease free interval (continuous) 0.29 --
Intent (curative vs. palliative) 0.35 --
Pancreatectomy (distal vs. proximal) 0.47 --
Metastasectomy vs. en bloc resection 0.01 0.13
Extent of resection (R0 vs R1/2) 0.04 0.05
Table 3: Likelihood of R0 resection by characteristic (n = 29 
patients).
Characteristic R0 R1 or R2
Intent of resection
Curative (n = 22) 17 (77%) 5 (23%)
Palliative (n = 7) 0 7 (100%)
Type of resection
En bloc for direct extension of primary 
malignancy (n = 22)
12(55%) 10 (45%)
Resection of metastasis to pancreas (n = 
7)
5 (71%) 2 (29%)
Site of primary tumor
Colorectal carcinoma (n = 9) 5 (56%) 4 (44%)
Gastric carcinoma (n = 8) 4 (50%) 4 (50%)
Renal cell carcinoma (n = 5) 3 (60%) 2 (40%)
Other site (n = 7) 5 (71%) 2 (29%)
Survival for R0 resection as compared to R1 or R2 resection Figure 1
Survival for R0 resection as compared to R1 or R2 
resection. The solid line represents patients with R0 resec-
tion, and the dashed line represents patients with R1 or R2 
resection.World Journal of Surgical Oncology 2007, 5:145 http://www.wjso.com/content/5/1/145
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The patient population in this study was somewhat
younger than typical patients undergoing pancreatectomy
for pancreatic cancer, reflecting our willingness to pursue
more aggressive surgical approaches in young, healthy
patients. However, age was not a predictor of outcome.
The majority of pancreatectomies were performed for can-
cers of gastrointestinal origin (most commonly colorectal
carcinoma), and often for locally advanced disease. Meta-
chronous spread of disease to the pancreas most com-
monly was of renal origin, as has been demonstrated
previously [3,8-11]. Non-gastrointestinal primaries con-
ferred improved overall survival as compared to gastroin-
testinal primaries, regardless of the completeness of
resection.
In this study, we observed a median overall survival of 12
months. This is less than the survival rates reported in pre-
vious studies [1,3,5-11]. There are several possible expla-
nations for this finding. Many previous reports of
resection of pancreatic metastases include patient popula-
tions that were primarily or exclusively composed of
patients with renal cell carcinoma. It is well known that
metastases from renal cell carcinoma may present at a pro-
longed interval after resection of the primary, and that
long-term survival of up to 10 years after resection of the
metastatic lesion is often achieved [8-11]. Although there
were five patients in our series with renal cell carcinoma,
most patients had GI malignancies, which are generally
characterized by shorter disease-free interval and more
aggressive tumor biology. In addition, our series included
12 patients (41%) who had R1 or R2 resections.
Several recent reports have demonstrated the utility of
resection of colon carcinoma en bloc with pancreaticodu-
odenectomy for locally advanced disease [14-18]. Kama et
al detailed the outcome of four patients who underwent
en bloc pancreaticoduodenectomy with right hemicolec-
tomy (plus resection of liver segments V and VI in one
patient) for locally invasive right colon cancer [14]. There
was one postoperative mortality but the remaining three
patients had disease-free survival of 14–41 months. Ber-
rospi et al studied three patients having en bloc resection
for colon cancers involving the pancreas and duodenum;
all were alive without evidence of disease at 10, 30, and
113 months, respectively [15]. Similarly, reports by Koea
and Curley upon 8 and 12 patients, respectively, undergo-
ing extended resections for colon carcinomas invading the
duodenum or pancreatic head revealed low mortality and
extended survival [16,17]. Finally, Kapoor et al recently
evaluated their experience of 11 patients undergoing en
bloc resection of adjacent organs for right colon cancer: six
had en bloc pancreaticoduodenectomy; three, en bloc
local excision of duodenal wall; one, en bloc resection of
segments V and VI of the liver; and one, en bloc distal gas-
trectomy [18]. Median disease-free survival among this
group of patients was 54 months. These results suggest
that there may be a subgroup of patients with colorectal
carcinoma, particularly right colon carcinoma, who have
locally invasive disease involving the duodenum or pan-
creas that responds well to aggressive resection.
Many of the reports in the literature of resection for pan-
creatic metastases or primaries with extension to the pan-
creas include only those patients with margin-negative
resections. For example, Pingpank et al, reported on a
population of 35 patients with similar distribution of pri-
mary tumor histologies to that reported in this study [19].
However, only patients with negative margins were
included. Median overall survival of 46 months was
achieved. In contrast, the report by Z'Graggen et al,
included 6 of 10 patients who underwent palliative proce-
dures only [6]. In this study, a median overall survival of
19 months was observed. Thus, the lower overall survival
observed in our study may possibly be explained by both
the predominance of patients with GI primaries, and the
fact that patients undergoing R1 or R2 resections were
included. In order to truly understand the risks and bene-
fits of pancreatectomy for non-pancreatic tumors, we felt
it necessary to include all patients undergoing pancreatec-
tomy, including those who had R1 or R2 resection.
As such, we demonstrated that R0 resection, as compared
to R1 or R2, in addition to non-GI primary versus GI pri-
mary, provided statistically better survival. A univariate
analysis showed R0 resection, non-GI primary, and resec-
tion of metastatic disease to the pancreas versus en bloc
excision for extension to the pancreas to be predictors of
survival. However, only R0 resection was predictive of sur-
vival by multivariate analysis. This result again empha-
sizes the fact that complete resection of metastatic or
locally advanced lesions must be achieved in order to
affect survival.
Conclusion
Our experience suggests that pancreatic resection for non-
pancreatic malignancies can be completed with minimal
mortality in experienced centers. This study, albeit rela-
tively small, represents one of the larger experiences to
date. Patients with non-GI primary tumors had better sur-
vival than those with GI primaries; however, incomplete
(R1 or R2) resection resulted in the poorest overall sur-
vival, regardless of site of origin. Thus, pancreatectomy for
pancreatic metastases or tumors with direct extension to
the pancreas should only be undertaken if complete resec-
tion is anticipated.
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